A citation-based method for searching scientific literature

Thomas Aparicio, Nathalie Cozic, Christelle de la Fouchardière, Emeline Meriaux, Jérome Plaza, Laurent Mineur, Rosine Guimbaud, Emmanuelle Samalin, Florence Mary, Thierry Lecomte, Carlos Gomez-Roca, Paul-Arthur Haineaux, Alain Gratet, Jannick Selves, Yves Menu, Nikias Colignon, Laetitia Johnson, Frédéric Legrand, Gilles Vassal. Target Oncol 2021
Times Cited: 8







List of co-cited articles
28 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
50

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
246
37

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
37

A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors.
Eric Van Cutsem, Boguslawa Karaszewska, Yoon-Koo Kang, Hyun Cheol Chung, Veena Shankaran, Salvatore Siena, Ning F Go, Hui Yang, Marco Schupp, David Cunningham. Clin Cancer Res 2019
40
37

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
142
25

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck,[...]. N Engl J Med 2020
222
25

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip,[...]. J Clin Oncol 2018
155
25

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma,[...]. J Clin Oncol 2016
369
25

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.
Martin van den Bent, Analia Azaro, Filip De Vos, Juan Sepulveda, W K Alfred Yung, Patrick Y Wen, Andrew B Lassman, Markus Joerger, Ghazaleh Tabatabai, Jordi Rodon,[...]. J Neurooncol 2020
14
25


MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
James Bean, Cameron Brennan, Jin-Yuan Shih, Gregory Riely, Agnes Viale, Lu Wang, Dhananjay Chitale, Noriko Motoi, Janos Szoke, Stephen Broderick,[...]. Proc Natl Acad Sci U S A 2007
25

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
D Moro-Sibilot, N Cozic, M Pérol, J Mazières, J Otto, P J Souquet, R Bahleda, M Wislez, G Zalcman, S D Guibert,[...]. Ann Oncol 2019
69
25

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.
D P Bottaro, J S Rubin, D L Faletto, A M Chan, T E Kmiecik, G F Vande Woude, S A Aaronson. Science 1991
25

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.
P Schöffski, A Wozniak, S Stacchiotti, P Rutkowski, J-Y Blay, L H Lindner, S J Strauss, A Anthoney, F Duffaud, S Richter,[...]. Ann Oncol 2017
47
25

Safety and Tolerability of c-MET Inhibitors in Cancer.
Alberto Puccini, Nagore I Marín-Ramos, Francesca Bergamo, Marta Schirripa, Sara Lonardi, Heinz-Josef Lenz, Fotios Loupakis, Francesca Battaglin. Drug Saf 2019
44
25

Oesophageal cancer.
Elizabeth C Smyth, Jesper Lagergren, Rebecca C Fitzgerald, Florian Lordick, Manish A Shah, Pernilla Lagergren, David Cunningham. Nat Rev Dis Primers 2017
388
25

A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Lipika Goyal, Hui Zheng, Matthew B Yurgelun, Thomas A Abrams, Jill N Allen, James M Cleary, Michelle Knowles, Eileen Regan, Amanda Reardon, Anna Khachatryan,[...]. Cancer 2017
65
25

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Jianjiong Gao, Bülent Arman Aksoy, Ugur Dogrusoz, Gideon Dresdner, Benjamin Gross, S Onur Sumer, Yichao Sun, Anders Jacobsen, Rileen Sinha, Erik Larsson,[...]. Sci Signal 2013
25

Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.
Jeeyun Lee, Seung Tae Kim, Kyung Kim, Hyuk Lee, Iwanka Kozarewa, Peter G S Mortimer, Justin I Odegaard, Elizabeth A Harrington, Juyoung Lee, Taehyang Lee,[...]. Cancer Discov 2019
77
25

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.
Manish A Shah, Yung-Jue Bang, Florian Lordick, Maria Alsina, Meng Chen, Stephen P Hack, Jean Marie Bruey, Dustin Smith, Ian McCaffery, David S Shames,[...]. JAMA Oncol 2017
156
25

A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer.
Daisuke Sakai, Hyun Cheol Chung, Do-Youn Oh, Se Hoon Park, Shigenori Kadowaki, Yeul Hong Kim, Akihito Tsuji, Yoshito Komatsu, Yoon-Koo Kang, Kazunori Uenaka,[...]. Cancer Chemother Pharmacol 2017
19
25

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, André M Murad, Salah-Eddin Al-Batran, David H Ilson, Sergei Tjulandin, Evengy Gotovkin, Boguslawa Karaszewska, Igor Bondarenko,[...]. Lancet Oncol 2017
181
25

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
Robert D Schreiber, Lloyd J Old, Mark J Smyth. Science 2011
25

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
Jochen K Lennerz, Eunice L Kwak, Allison Ackerman, Michael Michael, Stephen B Fox, Kristin Bergethon, Gregory Y Lauwers, James G Christensen, Keith D Wilner, Daniel A Haber,[...]. J Clin Oncol 2011
360
25

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.
Yazhuo Zhang, Mengfang Xia, Ke Jin, Shufei Wang, Hang Wei, Chunmei Fan, Yingfen Wu, Xiaoling Li, Xiayu Li, Guiyuan Li,[...]. Mol Cancer 2018
233
25

HER2-targeted therapies in gastric cancer.
Yinxing Zhu, Xuedan Zhu, Xiaowei Wei, Cuiju Tang, Wenwen Zhang. Biochim Biophys Acta Rev Cancer 2021
16
25


Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?
Witthawat Ariyawutyakorn, Siriwimon Saichaemchan, Marileila Varella-Garcia. J Cancer 2016
23
25

Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes.
Mizuho Nakayama, Katsuya Sakai, Atsuko Yamashita, Takahiro Nakamura, Yoshinori Suzuki, Kunio Matsumoto. Cytokine 2013
19
12

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
L Schmidt, F M Duh, F Chen, T Kishida, G Glenn, P Choyke, S W Scherer, Z Zhuang, I Lubensky, M Dean,[...]. Nat Genet 1997
12

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Gautam Maulik, Takashi Kijima, Patrick C Ma, Sudip K Ghosh, Jeffrey Lin, Geoffrey I Shapiro, Erik Schaefer, Elena Tibaldi, Bruce E Johnson, Ravi Salgia. Clin Cancer Res 2002
199
12

Disease-dependent reciprocal phosphorylation of serine and tyrosine residues of c-Met/HGF receptor contributes disease retardation of a transgenic mouse model of ALS.
Keiichi Kadoyama, Hiroshi Funakoshi, Wakana Ohya-Shimada, Takahiro Nakamura, Kunio Matsumoto, Shogo Matsuyama, Toshikazu Nakamura. Neurosci Res 2009
7
14

Prognostic role of c-Met in head and neck squamous cell cancer tissues: a meta-analysis.
Vit Vsiansky, Jaromir Gumulec, Martina Raudenska, Michal Masarik. Sci Rep 2018
13
12

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Toni K Choueiri, Susan Halabi, Ben L Sanford, Olwen Hahn, M Dror Michaelson, Meghara K Walsh, Darren R Feldman, Thomas Olencki, Joel Picus, Eric J Small,[...]. J Clin Oncol 2017
426
12


Interplay between scatter factor receptors and B plexins controls invasive growth.
Paolo Conrotto, Simona Corso, Sara Gamberini, Paolo Maria Comoglio, Silvia Giordano. Oncogene 2004
142
12

c-Met expression of thyroid tissue with special reference to papillary carcinoma.
T Oyama, E Ichimura, T Sano, K Kashiwabara, T Fukuda, T Nakajima. Pathol Int 1998
22
12

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
Anna Li, Jin-Ji Yang, Xu-Chao Zhang, Zhou Zhang, Jian Su, Lan-Ying Gou, Yu Bai, Qing Zhou, Zhenfan Yang, Han Han-Zhang,[...]. Clin Cancer Res 2017
51
12


Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?
Elizabeth Charytonowicz, Carlos Cordon-Cardo, Igor Matushansky, Mel Ziman. Cancer Lett 2009
108
12

C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas.
Paulina Marona, Judyta Górka, Jerzy Kotlinowski, Marcin Majka, Jolanta Jura, Katarzyna Miekus. Cells 2019
13
12

The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Xing Huang, Guangming Gan, Xiaoxiao Wang, Ting Xu, Wei Xie. Autophagy 2019
84
12

Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.
Klaudia Skrzypek, Anna Kusienicka, Barbara Szewczyk, Tomasz Adamus, Ewa Lukasiewicz, Katarzyna Miekus, Marcin Majka. Oncotarget 2015
24
12



Predictive role of the overexpression for CXCR4, C-Met, and VEGF-C among breast cancer patients: A meta-analysis.
Fang Wang, Shanshan Li, Yueguang Zhao, Kunxian Yang, Minju Chen, Heng Niu, Jingyu Yang, Ying Luo, Wenru Tang, Miaomiao Sheng. Breast 2016
21
12

Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.
Kacper Jankowski, Magda Kucia, Marcin Wysoczynski, Ryan Reca, Dongling Zhao, Ela Trzyna, John Trent, Stephen Peiper, Marek Zembala, Janina Ratajczak,[...]. Cancer Res 2003
154
12

A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.
Aflah Roohullah, Adam Cooper, Anna J Lomax, Jennifer Aung, Alan Barge, Lilian Chow, Mark McHale, Jayesh Desai, James R Whittle, Ben Tran,[...]. Invest New Drugs 2018
16
12

Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.
Hyori Kim, Jeonghwan Youk, Yaewon Yang, Tae-Yong Kim, Ahrum Min, Hye-Seon Ham, Seongcheol Cho, Kyung-Hun Lee, Bhumsuk Keam, Sae-Won Han,[...]. J Cancer Res Clin Oncol 2016
7
14

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.
Gromoslaw A Smolen, Raffaella Sordella, Beth Muir, Gayatry Mohapatra, Anne Barmettler, Heidi Archibald, Woo J Kim, Ross A Okimoto, Daphne W Bell, Dennis C Sgroi,[...]. Proc Natl Acad Sci U S A 2006
421
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.